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Ethylmalonic encephalopathy (EE) is a severe mitochondrial disease of 
early infancy clinically characterized by a combination of developmental 
delay, progressive pyramidal signs, and vascular lesions including petechial 
purpura, orthostatic acrocyanosis, and chronic hemorrhagic diarrhea. 
Biochemical hallmarks of the disease are persistently high level of lactate, 
and C4–C5-acylcarnitines in blood, markedly elevated urinary excretion of 
methylsuccinic and ethylmalonic (EMA) acids. Here we report two patients 
with EE as a 16-months-old male infant and a 2-yr-old boy referred to 
Pediatric Neurology Clinic in Children’s Medical Center, Tehran-Iran that in 
one patient genetic analysis revealed a homozygous mutation of the ETHE1 
gene in favor of ethylmalonic acidemia.
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Introduction 
Ethylmalonic encephalopathy (EE) (OMIM602473), is a very rare mitochondrial 
disorder caused by mutations in the ETHE1 gene localized on chromosome 19q13 
(1). The ETHE1 protein is a 30 KD polypeptide located on the mitochondrial, 
Fe-containing sulfur dioxygenase (SDO) activity and involved in catabolism of 
sulfide. Loss of function ETHE1 caused by impaired activity of this protein leads 
to the accumulation of H2S (dihydrogen sulfide) and derivative thiosulphate in 
crucial tissues, including liver, brain and colonic mucosa. Increased concentration 
of these toxic products inhibits SCAD (short-chain Acyl-CoA dehydrogenase 
deficiency) and COX (Cytochrome c oxidase) activities; therefore, accounting for 
EMA aciduria and high serum levels of C4- and C5-acylcarnitines and lactate (2). 
Ethylmalonic encephalopathy is clinically characterized by the early onset of 
neurological degeneration, hypotonia, psychomotor retardation, seizure, spastic 
tetraplegia, Leigh-like syndrome, recurrent petechiae, chronic hemorrhagic 
diarrhea and orthostatic acrocyanosis, leading to death in the first years of life. 
The accumulation of H2S damages the endothelial cells and vasodilation, which 
account for the petechiae and the acrocyanosis. H2S overload in colonic mucosa 
result in ulcerative colitis by reduced detoxification (3, 4). 
The prognosis is poor; therefore, half of the patients die within the first 2 years of life 
from metabolic decompensation (5). We emphasize that physician should consider 
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Case 2
A 2-year-old boy was referred to Pediatric Neurology 
department of Mofid Children Hospital, Tehran-Iran for 
evaluation of neurodevelopmental delay. He was the first 
child of a consanguineous marriage, born with a weight 
of 3100 gr, length of 50 cm, and a head circumference of 
36 cm. He had rolling and creeping but did not have the 
ability to sit, standing and walking. He could not speak. 
He had a history of admission for bloody stool after 20 
days of birth but hematologic and intestinal evaluations 
did not confirm abnormal evidence. Neurological exam 
showed cerebral hypotonia. MRI revealed abnormal 
signal intensity in periventricular white matter and basal 
ganglia. Laboratory exams showed no specific change 
but serum lactic acid was mildly elevated (3 MM; normal 
range: 0.7–1.8). According to clinical manifestations 
and suspicion to neurometabolic disorders, metabolic 
evaluation included urine organic acid was requested 
that showed significant elevated ethylmalonic acid 
(2125 MM/M creatinine, normal<17). Genetic study to 
confirm the diagnosis of EE was not done in this patient.
Discussion
An increasing number of patients with EE are being 
diagnosed. The actual incidence of the condition 
may be significantly underestimated because the 
biochemical phenotype and clinical manifestations may 
be misinterpreted to other metabolic disorders (6). 
Overall, 145 patients with different clinical 
manifestations have been reported since 1993 (3-
20). The cardinal symptoms of EE are neurologic and 
vascular but congenital anomalies of the central nervous 
system (tethered cord, Chiari I malformation), moderate 
hydronephrosis and undescended testes, cardiac 
involvement, respiratory failure, nephrotic syndrome, 
crescentic glomerulonephritis, articular hyperlaxity, 
Neonatal Marfan phenotype, west syndrome and 
dysmorphic feature have been described (3-20). Most 
of patients have a severe form of the disorder with 
infantile onset and die within the early years of life. A 
few patients have a chronic form of the disease (6). 
Our patients showed neurologic and vascular symptoms 
include hypotonia, developmental delay, refractory 
seizure, petechiae, and bloody stool. Case 2 was managed 
mainly for hematologic and gastrointestinal disease 
Ethylmalonic Encephalopathy in all patients with 
neurological deterioration, lactic acidosis combination 
with vascular manifestations. 
Here we report two patients with EE as a 16-months-old 
male infant and a 2-yr-old boy.
Case presentation
Patient consent: Written informed consent was 
obtained from parents.
Case 1
A 16-months-old male infant was referred to Pediatric 
Neurology Clinic in Children’s Medical Center, 
Tehran-Iran because of seizure, developmental delay, 
and petechiae in 2016. He was the second child of 
consanguineous parents, born with a weight of 2500 
gr, length of 44cm, and a head circumference of 36 
cm. The first child had dead at the age of three years 
following frequent severe convulsions without making 
a diagnosis. On neurologic examination, he had global 
developmental delay and axial hypotonia, exaggerated 
deep tendon reflexes, inability to sitting and standing 
but he was able to keep the head. In addition, he had 
diffuse petechiae on his examination (Figure 1, 2). 
Laboratory tests revealed an elevation of leucine 
(315µmol/L, norm30-246) and isoleucine (200µmol/L, 
norm 6-122) in serum amino acid analysis. Lactic acid 
levels had been elevated in plasma (5 MM; normal 
range: 0.7–1.8) and in CSF (7.4 MM; normal range: 
<2.2) with increased lactate/pyruvate ratio (19 and 24 
in plasma and CSF, respectively). Serum ammonia and 
acylcarnitine profile, liver function test were normal. 
Urine organic acid showed high ethylmalonic acid 
(1200 MM/M creatinine, norm<17). MRI (Magnetic 
Resonance Imaging) showed abnormal signal in basal 
ganglia especially caudate and dentate nucleus and 
some degree of atrophy in corpus callosum. To confirm 
the diagnosis of EE, mutation analysis was performed 
that revealed a homozygote ETHE1 gene mutation 
compatible with diagnosis of ethylmalonic acidemia. 
Currently, the patient is 2 yr old; he has developmental 
delay, axial hypotonia, hypertonia, and hyperreflexia 
in limbs. He has also episodes of generalized seizures 
despite antiepileptic treatment. At the time being, he is 
mainly treated with mitochondrial cocktail.
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investigated and resolved.
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Fig 1. Petechiae lesions on the thigh of the patient 1
 
Fig 2. Petechiae lesions on the leg of the patient1
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